Please login to the form below

Fasenra

This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.

as AstraZeneca’s asthma injection Fasenra(benralizumab).

Nucala works in rare inflammatory disease, says GSK

GSK is trying to keep the first-to-market IL-5 inhibitor ahead of other drugs in the class, particularly AstraZeneca’s Fasenra (benralizumab) which is gaining ground fast with
AZ reports growth again in Q3, driven by oncology and China sales

AZ’s respiratory franchise also grew 18% to $1.3bn – although the company saw a 4% decline in sales of Symbicort, this was offset by the growth of Pulmicort and Fasenra,
Tecentriq’s triple negative breast cancer use among key CHMP nods

The company also received a positive opinion for a new self-administration option for Fasenra (benralizumab) via a pre-filled, single-use auto-injector, rivalling similar moves from GSK and its
GSK’s Nucala gets boost with self-administration approval

it. This still leaves it at a disadvantage to Fasenra, which is administered just once every eight weeks. ... This bad news has been tempered by disappointing results for AZ's rival Fasenra in the same setting.
Sanofi's Dupixent gains asthma approval in Europe

This puts it into direct competition with some established players in that field, GSK's Nucala and AstraZeneca's Fasenra..

More from news
Approximately 7 fully matching, plus 17 partially matching documents found.

The long and winding road to asthma breakthroughs

But GSK is not alone in the IL-5 inhibitor arena. AstraZeneca’s Fasenra is making waves with its eight-week dosing schedule and $296m in first-half sales – a 244%
AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...